Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
121 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2015', provides an overview of the Human papillomavirus (HPV) Associated Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Human papillomavirus (HPV) Associated Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Human papillomavirus (HPV) Associated Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Overview 11 Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis 12 Human papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 13 Human papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 16 Human papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Human papillomavirus (HPV) Associated Cancer - Products under Development by Companies 20 Human papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 22 Human papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 23 3SBio Inc. 23 Abivax 24 Admedus Ltd 25 Antigen Express, Inc. 26 Bionor Pharma ASA 27 Cancer Therapeutics CRC Pty Ltd 28 Etubics Corporation 29 EyeGene, Inc. 30 Formune S.L. 31 Genexine, Inc. 32 iBio, Inc. 33 Inovio Pharmaceuticals, Inc. 34 MedImmune, LLC 35 Merck & Co., Inc. 36 Novartis AG 37 Onconova Therapeutics, Inc. 38 Prima BioMed Ltd. 39 Profectus BioSciences, Inc. 40 Redbiotec AG 41 Sirnaomics, Inc. 42 Theravectys S.A. 43 Transgene SA 44 Vaccibody AS 45 Virometix AG 46 ViroStatics, srl 47 Human papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Combination Products 49 Assessment by Target 50 Assessment by Mechanism of Action 52 Assessment by Route of Administration 54 Assessment by Molecule Type 56 Drug Profiles 58 ABX-318 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 AEH-10p - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 alpelisib - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Antibodies to Target E7 for HPV Associated Cancer - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Cell Therapy to Target HPV-16 E6 Protein for Papillomavirus Associated Cancers - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 durvalumab + tremelimumab - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 EDA-HPVE7 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 EG-HPV - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Gene Therapy for Papillomavirus Associated Cervical Carcinoma - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 GX-188E - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 HPV Vaccine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 human papillomavirus (7-valent) vaccine - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 human papillomavirus (9-valent) vaccine - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 human papillomavirus [Serotype 16] vaccine - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 human papillomavirus vaccine - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 human papillomavirus vaccine - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 INO-3106 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 INO-3112 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 RBT-201 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 rigosertib sodium - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 SSS-08 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 STP-909 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 STP-911 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 TG-4001 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Vacc-HPV - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Vaccine for HPV Associated Cancer - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Vaccine for HPV Associated Cancers - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Vaccine for HPV Associated Cancers - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Vaccine for HPV Associated Head and Neck Cancer - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Vaccine for HPV Associated Skin Cancer - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Vaccines for HPV Associated Cervical Cancer - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 VB-1016 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Vicoryx - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 Human papillomavirus (HPV) Associated Cancer - Recent Pipeline Updates 105 Human papillomavirus (HPV) Associated Cancer - Dormant Projects 115 Human papillomavirus (HPV) Associated Cancer - Product Development Milestones 116 Featured News & Press Releases 116 Dec 10, 2014: FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV 116 Mar 05, 2014: Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza 117 Nov 04, 2013: Merck's Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study 117 Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine 119 Appendix 120 Methodology 120 Coverage 120 Secondary Research 120 Primary Research 120 Expert Panel Validation 120 Contact Us 120 Disclaimer 121
List of Tables Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2015 11 Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2015 16 Comparative Analysis by Late Stage Development, H1 2015 17 Comparative Analysis by Clinical Stage Development, H1 2015 18 Comparative Analysis by Early Stage Development, H1 2015 19 Products under Development by Companies, H1 2015 20 Products under Development by Companies, H1 2015 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2015 22 Human papillomavirus (HPV) Associated Cancer - Pipeline by 3SBio Inc., H1 2015 23 Human papillomavirus (HPV) Associated Cancer - Pipeline by Abivax, H1 2015 24 Human papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H1 2015 25 Human papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H1 2015 26 Human papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H1 2015 27 Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2015 28 Human papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H1 2015 29 Human papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H1 2015 30 Human papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H1 2015 31 Human papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H1 2015 32 Human papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H1 2015 33 Human papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 34 Human papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H1 2015 35 Human papillomavirus (HPV) Associated Cancer - Pipeline by Merck & Co., Inc., H1 2015 36 Human papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H1 2015 37 Human papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H1 2015 38 Human papillomavirus (HPV) Associated Cancer - Pipeline by Prima BioMed Ltd., H1 2015 39 Human papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H1 2015 40 Human papillomavirus (HPV) Associated Cancer - Pipeline by Redbiotec AG, H1 2015 41 Human papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H1 2015 42 Human papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys S.A., H1 2015 43 Human papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H1 2015 44 Human papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H1 2015 45 Human papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H1 2015 46 Human papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics, srl, H1 2015 47 Assessment by Monotherapy Products, H1 2015 48 Assessment by Combination Products, H1 2015 49 Number of Products by Stage and Target, H1 2015 51 Number of Products by Stage and Mechanism of Action, H1 2015 53 Number of Products by Stage and Route of Administration, H1 2015 55 Number of Products by Stage and Molecule Type, H1 2015 57 Human papillomavirus (HPV) Associated Cancer Therapeutics - Recent Pipeline Updates, H1 2015 105 Human papillomavirus (HPV) Associated Cancer - Dormant Projects, H1 2015 115
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.